Intermediates for the preparation of Oxazolidinedione and Thiazolidinedione derivatves

Abstract: A compound of formula (XIV): wherein: each of Y and Y' independently represents an oxygen atom or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom. a hydroxy group, a nitro group, an aralkyl group, or a group of formula -NR a R b , wherein R a and R b are the same or different and each represents a hydrogen atom, an alkyl group, an aralkyl group, an aryl group, an aliphatic carboxylic acyl group, an aliphatic carboxylic acyl group which is substituted by an aryl group, or an aromatic carboxylic acyl group, m is an integer of from 1 to 5; Q represents a lower alkoxycarbonyl group, a formyl group, a protected formyl group or a carboxyl group; and salts thereof. The compound of formula (XIV) is of use as an intermediate in the synthesis of heterocyclic compounds having hypoglycemic and anti-diabetic activities.

Description: The present invention relates to a series of heterocyclic compounds useful as intermediates in the production of further heterocyclic compounds having hypoglycemic and anti-diabetic activities, and provides processes for their preparation. It is known that compounds which, like those of the present invention, contain, inter alia , a thiazolidinedione or oxazolidinedione group attached, via a methylene or methylidene group, to a benzene ring have this type of activity. Compounds of this general type are disclosed in European Patent Publications No. 008 203, 139 421, 441 605, 208 420, 528 734, 177 353, 306 228 and 356 214, and in WO 92/07850, 92/07839, 91/07107, 92/02520 and 92/03425. We have now discovered that the inclusion in such compounds of certain specific bicyclic nitrogen-containing ring systems results in compounds of much improved activity. EP-A-676398, from which the present application is divided, provides compounds of formula (I): wherein: X represents an indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group which is unsubstituted or is substituted by at least one substituent selected from substituents α, defined below; Y represents an oxygen atom or a sulphur atom; Z represents a group of formula (i), (ii), (iii), (iv) or (v) : R represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms, a halogen atom, a hydroxy group, a nitro group, an aralkyl group in which an alkyl group having from 1 to 5 carbon atoms is substituted by an aryl group having from 6 to 10 ring carbon atoms, or a group of formula -NR a R b , wherein R a and R b are the same or different and each represents a hydrogen atom, an alkyl group having from 1 to 8 carbon atoms, an aralkyl group in which an alkyl group having from 1 to 5 carbon atoms is substituted by an aryl group having from 6 to 10 ring carbon atoms, an aryl group having from 6 to 10 ring carbon atoms, an aliphatic carboxylic acyl group having from 1 to 11 carbon atoms, an aliphatic carboxylic acyl group which has from 2 to 6 carbon atoms and which is substituted by an aryl group having from 6 to 10 ring carbon atoms, or an aromatic carboxylic acyl group in which the aryl part has from 6 to 10 ring carbon atoms, m is an integer of from 1 to 5; each of said substituents α represents an alkyl group having from 1 to 4 carbon atoms, an aryl group having from 6 to 10 carbon atoms, a trifluoromethyl group, an alkylthio group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms, a benzyloxy group, a halogen atom, a hydroxy group, an acetoxy group, a phenylthio group, a nitro group, an aralkyl group, or a group of formula -NR a R b , wherein R a and R b are as defined above; said aryl groups and the aryl parts of said aralkyl groups included in substituents α are carbocyclic aromatic groups having from 6 to 10 ring carbon atoms and are unsubstituted or are substituted at least one substituent selected from substituents β, defined below; each of said substituents β represents an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms, a halogen atom, a hydroxy group, a nitro group, a phenyl group, a trifluoromethyl group, or a group of formula -NR a R b , wherein R a and R b are as defined above; and salts thereof. Preferred compounds of formula (I), processes for their preparation, their activity and compositions containing them are described in EP-A-676398 to which reference is made. The present invention provides a compound of formula (XIV) : wherein: each of Y and Y' independently represents an oxygen atom or a sulfur atom; R represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms, a halogen atom, a hydroxy group, a nitro group, an aralkyl group in which an alkyl group having from 1 to 5 carbon atoms is substituted by an aryl group having from 6 to 10 ring carbon atoms, or a group of formula -NR a R b , wherein R a and R b are the same or different and each represents a hydrogen atom, an alkyl group having from 1 to 8 carbon atoms, an aralkyl group in which an alkyl group having from 1 to 5 carbon atoms is substituted by an aryl group having from 6 to 10 ring carbon atoms, an aryl group having from 6 to 10 ring carbon atoms, an aliphatic carboxylic acyl group having from 1 to 11 carbon atoms, an aliphatic carboxylic acyl group which has from 2 to 6 carbon atoms and which is substituted by an aryl group having from 6 to 10 ring carbon atoms, or an aromatic carboxylic acyl group in which the aryl part has from 6 to 10 ring carbon atoms; m is an integer of from 1 to 5; and Q represents a lower alkoxycarbonyl group, a formyl group, a protected formyl group, a protected formyl group or a carboxyl group; and salts thereof. The invention also provides processes for the preparation of the compounds of the present invention, which processes are described in more detail hereafter. The compounds of the present invention are useful as intermediates in the preparation of compounds of formula (I), described and exemplified in EP-A-676398 to which reference is made. Thus, it is an advantage of the present invention that a series of new chemical compounds which may be regarded as thiazolidine and oxazolidine derivatives or as ring-opened derivatives thereof is provided. It is a further, and more specific, advantage of the present invention to provide such compounds, at least some of which may be useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications. Where R represents an alkyl group, this may be a straight or branched chain alkyl group having from 1 to 4 carbon atoms, and examples include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and t-butyl groups, of which we prefer the methyl group. Where R represents an alkoxy group, this may be a straight or branched chain alkoxy group having from 1 to 4 carbon atoms, and examples include the methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and t-butoxy groups, of which we prefer the methoxy group. Where R represents a halogen atom, it may be, for example, a bromine, chlorine, fluorine or iodine atom, of which we prefer the bromine, chlorine and fluorine atoms, the chlorine atom being most preferred. Where R represents an aralkyl group, the alkyl part of this group has from 1 to 5 carbon atoms and may be a straight or branched chain group which is substituted by an aryl group, which itself is as defined and exemplified below. In all, the aralkyl group preferably has from 7 to 11 carbon atoms. Examples of the alkyl part of such groups include the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl and t-pentyl groups (preferably the methyl and ethyl groups). Examples of aryl groups are given hereafter. Specific examples of such aralkyl groups include the benzyl, 2-phenylethyl ( = phenethyl), 1-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-phenylpropyl, 4-phenylbutyl, 1-phenylbutyl, 5-phenylpentyl, 1-naphthylmethyl and 2-naphthylmethyl groups, of which the phenethyl and benzyl groups are preferred, the benzyl group being most preferred. Alternatively, R may represent an amino group or substituted amino group of formula -NR a R b , where R a and R b , which may be the same or different are selected from the following: (1) Hydrogen atoms; (2) Alkyl groups having from 1 to 8 carbon atoms, which may be straight or branched chain groups, for example the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, 2-pentyl, 3-pentyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 2-hexyl, 3-hexyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 3,3-dimethylpentyl, octyl, 1-methylheptyl, 2-ethylhexyl and 1,1,3,3-tetramethylbutyl groups, of which we prefer those straight and branched chain alkyl groups having from 1 to 6 carbon atoms, and most prefer those straight or branched chain alkyl groups having from 1 to 4 carbon atoms; the methyl and ethyl groups are most preferred; (3) Aralkyl groups as defined and exemplified above in relation to the group which may be represented by R, and preferably such groups having from 7 to 11 carbon atoms; (4) Aryl groups having from 6 to 10 carbon atoms, for example, the phenyl, 1-naphthyl and 2-naphthyl groups; (5) Aliphatic carboxylic acyl groups, which may be straight or branched chain groups having from 1 to 11 carbon atoms, for example, the formyl, acetyl, propionyl, butyryl, isobutyryl, pivaloyl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl and undecanoyl groups; (6) Aliphatic carboxylic acyl groups which have from 2 to 6 carbon atoms and which are substituted by an aryl group as defined above, and each of which preferably has a total of from 8 to 12 carbon atoms; examples of the aliphatic acyl part of the group are those acyl groups having from 2 to 6 carbon atoms which are included among the aliphatic acyl groups represented by R a and R b above (preferably the acetyl and propionyl groups), and examples of the aryl part are included among those aryl groups listed above (preferably the phenyl and naphthyl groups, especially the phenyl group); specific examples of preferred aromatic-substituted aliphatic acyl groups include the phenylacetyl, 3-phenylpropionyl, 4-phenylbutyryl, 5-phenylpentanoyl, 6-phenylhexanoyl, α-methylphenylacetyl and α,α-dimethylphenylacetyl groups, of which the phenylacetyl group is preferred; (7) Carbocyclic aromatic carboxylic acyl groups, in which the aryl group is as defined and exemplified above (preferably the phenyl and naphthyl groups, especially the phenyl group); preferred groups are those having a total of from 7 to 11 carbon atoms, and examples include the benzoyl, 1-naphthoyl and 2-naphthoyl groups, of which the benzoyl group is preferred. Specific examples of such amino groups which may be represented by R include the following: (1) Substituted amino groups in which one of R a and R b represents a hydrogen atom and the other of R a and R b represents an alkyl group, such as the methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, sec-butylamino, t-butylamino, pentylamino, 2-pentylamino, 3-pentylamino, 2-methylbutylamino, 3-methylbutylamino, 1,1-dimethylpropylamino, 1,2-dimethylpropylamino, 2,2-dimethylpropylamino, hexylamino, 2-hexylamino, 3-hexylamino, 2-methylpentylamino, 3-methylpentylamino, 4-methylpentylamino, 1,1-dimethylbutylamino, 1,2-dimethylbutylamino, 1,3-dimethylbutylamino, 2,2-dimethylbutylamino, 2,3-dimethylbutylamino, 3,3-dimethylbutylamino, 1,1,2-trimethylpropylamino, 1,2,2-trimethylpropylamino, heptylamino, 2-heptylamino, 3-heptylamino, 4-heptylamino, 3,3-dimethylpentylamino, octylamino, 1-methylheptylamino, 2-ethylhexylamino and 1,1,3,3-tetramethylbutylamino groups; (2) Substituted amino groups, in which one of R a and R b represents a hydrogen atom and the other of R a and R b represents an aralkyl group, such as the benzylamino, 2-phenylethylamino, 1-phenylethylamino, 3-phenylpropylamino, 2-phenylpropylamino, 1-phenylpropylamino, 4-phenylbutylamino, 1-phenylbutylamino, 5-phenylpentylamino, 1-naphthylmethylamino and 2-naphthylmethylamino groups; (3) Substituted amino groups, in which one of R a and R b represents a hydrogen atom and the other of R a and R b represents an aryl group, such as the phenylamino, 1-naphthylamino and 2-naphthylamino groups; (4) Substituted amino groups, in which one of R a and R b represents a hydrogen atom and the other of R a and R b represents an aliphatic acyl group, such as the formamido, acetamido, propionamido, butyramido, isobutyramido, pivaloylamino, pentanoylamino, hexanoylamino, heptanoylamino, octanoylamino, nonanoylamino, decanoylamino and undecanoylamino groups; (5) Substituted amino groups, in which one of R a and R b represents a hydrogen atom and the other of R a and R b represents an aromatic-substituted aliphatic acyl group, such as the phenylacetamido, 3-phenylpropionamido, 4-phenylbutyramido, 5-phenylpentanoylamino, 6-phenylhexanoylamino, α-methylphenylacetamido and α,α-dimethylphenylacetamido groups; (6) Substituted amino groups, in which one of R a and R b represents a hydrogen atom and the other of R a and R b represents an aromatic acyl group, such as the benzamido, 1-naphthoylamino and 2-naphthoylamino; (7) Substituted amino groups, in which R a and R b both represent alkyl groups, which may be the same as or different from each other, such as the dimethylamino, diethylamino, N -methyl- N -ethylamino and N -methyl- N -pentylamino groups; (8) Substituted amino groups, in which one of R a and R b represents an alkyl group and the other of R a and R b represents an aralkyl group, such as the N -ethyl- N -benzylamino, N -t-butyl- N -benzylamino and N -hexyl- N -benzylamino groups; (9) Substituted amino groups, in which one of R a and R b represents an alkyl group and the other of R a and R b represents an aryl group, such as the N -methyl- N -phenylamino, N -ethyl- N -phenylamino and N -octyl- N -phenylamino groups; (10) Substituted amino groups, in which one of R a and R b represents an alkyl group and the other of R a and R b represents an aliphatic acyl group, such as the N -propyl- N -acetylamino, N -pentyl- N -propionylamino and N -ethyl- N -hexanoylamino groups; (11) Substituted amino groups, in which one of R a and R b represents an alkyl group and the other of R a and R b represents an aromatic-substituted carboxylic aliphatic acyl group, such as the N -ethyl- N -phenylacetylamino, N -isopropyl- N -(2-phenylpropionyl)amino and N -methyl- N -(6-phenylhexanoyl)amino groups; (12) Substituted amino groups, in which one of R a and R b represents an alkyl group and the other of R a and R b represents an aromatic acyl group, such as the N -methyl- N -benzoylamino, N -sec-butyl- N -benzoylamino and N -heptyl- N -benzoylamino groups; (13) Substituted amino groups, in which R a and R b both represent aralkyl groups, which may be the same as or different from each other, such as the dibenzylamino, N -benzyl- N -(3-phenylpropyl)amino and N -benzyl- N -(2-naphthylmethyl)amino groups; (14) Substituted amino groups, in which one of R a and R b represents an aralkyl group and the other of R a and R b represents an aryl group, such as the N -benzyl- N -phenylamino and N -(3-phenylpropyl)- N -phenylamino groups; (15) Substituted amino groups, in which one of R a and R b represents an aralkyl group and the other of R a and R b represents an aliphatic acyl group, such as the N -benzyl- N -acetylamino, N -benzyl- N -propionylamino and N -benzyl- N -pentanoylamino groups; (16) Substituted amino groups, in which one of R a and R b represents an aralkyl group and the other of R a and R b represents an aromatic-substituted aliphatic carboxylic acyl group, such as the N -benzyl- N -phenylacetylamino and N -benzyl- N -(4-phenylbutyryl)amino groups; (17) Substituted amino groups, in which one of R a and R b represents an aralkyl group and the other of R a and R b represents an aromatic acyl group, such as the N -benzyl- N -benzoylamino and N -(2-phenylethyl)- N -benzoylamino groups; (18) Substituted amino groups, in which R a and R b both represent aryl groups, which may be the same as or different from each other, such as the diphenylamino, N -(1-naphthyl)- N -phenylamino and N -(2-naphthyl)- N -phenylamino groups; (19) Substituted amino groups, in which one of R a and R b represents an aryl group and the other of R a and R b represents an aliphatic carboxylic acyl group, such as the N -phenyl- N -acetylamino, N -phenyl- N -propionylamino and N -phenyl- N -hexanoylamino groups; (20) Substituted amino groups, in which one of R a and R b represents an aryl group and the other of R a and R b represents an aromatic-substituted aliphatic carboxylic acyl group, such as the N -phenyl- N -phenylacetylamino and N -phenyl- N -(4-phenylbutyryl)amino groups; (21) Substituted amino groups, in which one of R a and R b represents an aryl group and the other of R a and R b represents an aromatic carboxylic acyl group, such as the N -phenyl- N -benzoylamino and N -phenyl- N -(2-naphthoyl)amino groups; (22) Substituted amino groups, in which R a and R b both represent aliphatic carboxylic acyl groups, which may be the same as or different from each other, such as the N , N -diacetylamino, N -acetyl N -propionylamino and N -butyryl- N -hexanoylamino groups; (23) Substituted amino groups, in which one of R a and R b represents an aliphatic carboxylic acyl group and the other of R a and R b represents an aromatic-substituted aliphatic carboxylic acyl group, such as the N -acetyl- N -phenylacetylamino, N -acetyl- N -(4-phenylbutyryl)amino and N -butyryl- N -phenylacetylamino groups; (24) Substituted amino groups, in which one of R a and R b represents an aliphatic carboxylic acyl group and the other of R a and R b represents an aromatic carboxylic acyl group, such as the N -acetyl- N -benzoylamino and N -butyryl- N -(2-naphthoyl)amino groups; (25) Substituted amino groups, in which R a and R b both represent aromatic-substituted aliphatic carboxylic acyl groups, which may be the same as or different from each other, such as the N , N -diphenylacetylamino, N -phenylacetyl- N -(2-phenylpropionyl)-amino and N -phenylacetyl- N -(4-phenylbutyryl)amino groups; (26) Substituted amino groups, in which one of R a and R b represents an aromatic-substituted aliphatic carboxylic acyl group and the other of R a and R b represents an aromatic carboxylic acyl group, such as the N -phenylacetyl- N -benzoylamino and N -phenylacetyl- N -(2-naphthoyl)amino groups; and (27) Substituted amino groups, in which R a and R b both represent aromatic carboxylic acyl groups, which may be the same as or different from each other, such as the N , N -dibenzoylamino and N -benzoyl- N -(2-naphthoyl)amino groups. Where part of the group R (eg, the aralkyl groups described above, or the groups R a and R b ) represents an aryl group having from 6 to 10 carbon atoms, this group is unsubstituted. Examples of the unsubstituted aryl groups include, for example, the phenyl, 1-naphthyl and 2-naphthyl groups. Where Q represents a lower alkoxycarbonyl group, this preferably has a total of from 2 to 7 carbon atoms (i.e. the alkoxy part has from 1 to 6 carbon atoms), and may be a straight or branched chain group. Examples of such groups include the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, isopentyloxycarbonyl, neopentyloxycarbonyl, 2-methylbutoxycarbonyl, 1-ethylpropoxycarbonyl, 4-methylpentoxycarbonyl, 3-methylpentoxycarbonyl, 2-methylpentyloxycarbonyl, 1-methylpentyloxycarbonyl, 3,3-dimethylbutoxycarbonyl, 2,2-dimethylbutoxycarbonyl, 1,1-dimethylbutoxycarbonyl, 1,2-dimethylbutoxycarbonyl, 1,3-dimethylbutoxycarbonyl, 2,3-dimethylbutoxycarbonyl, 2-ethylbutoxycarbonyl, hexyloxycarbonyl and isohexyloxycarbonyl groups. Of these, we prefer those alkoxycarbonyl groups having from 1 to 4 carbon atoms, preferably the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl and isobutoxycarbonyl groups, and most preferably the methoxycarbonyl and ethoxycarbonyl groups. Where Q represents a protected formyl group, examples of such groups are described in more detail below. Of the compounds of the present invention, we prefer those compounds of formula (XIV) and salts thereof, in which R represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms or a halogen atom. More preferred compounds of the present invention are those compounds of formula (XIV) and salts thereof, in which R represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms or a halogen atom. Still more preferred compounds of the present invention are those compounds of formula (XIV) and salts thereof, in which R represents a hydrogen atom, a methoxy group, an ethoxy group, a fluorine atom or a chlorine atom. Still more preferred compounds of the present invention are those compounds of formula (XIV) and salts thereof, in which R represents a hydrogen atom or a methoxy group. The most preferred compounds of the present invention are those compounds of formula (XIV) and salts thereof, in which R represents a hydrogen atom. The compounds of the present invention may contain a basic group in its molecule, and can thus be converted to salts with acids by conventional methods. There is no particular restriction on the nature of such salts, provided that, where the compounds are to be used medically, the compounds are pharmaceutically acceptable, that is it is not less active, or unacceptably less active, nor more toxic, or unacceptably more toxic, than the parent compound. However, where the compound is to be used for non-medical uses, e.g. as an intermediate in the preparation of other compounds, even this restriction does not apply, and there is then no restriction on the nature of the salts which may be formed. Examples of such salts include: salts with mineral acids, especially hydrohalic acids (such as hydrofluoric acid, hydrobromic acid, hydroiodic acid or hydrochloric acid), nitric acid, perchloric acid, carbonic acid, sulphuric acid or phosphoric acid; salts with lower alkylsulphonic acids, such as methanesulphonic acid, trifluoromethanesulphonic acid or ethanesulphonic acid; salts with arylsulphonic acids, such as benzenesulphonic acid or p -toluene-sulphonic acid; salts with organic carboxylic acids, such as acetic acid, fumaric acid, tartaric acid, oxalic acid, maleic acid, malic acid, succinic acid, benzoic acid, mandelic acid, ascorbic acid, lactic acid, gluconic acid or citric acid; and salts with amino acids, such as glutamic acid or aspartic acid. We prefer the pharmaceutically acceptable salts. Also, the compound of the present invention can be converted into a salt with a base by conventional methods. Examples of such salts include: salts with an alkali metal, such as sodium, potassium or lithium; salts with an alkaline earth metal, such as barium or calcium; and salts with another metal, such as magnesium or aluminum. We prefer the pharmaceutically acceptable salts. The compounds of formula (XIV) of the present invention can exist in the form of various isomers due to the presence of asymmetric carbon atoms. Thus, as a 2,4-dioxothiazolidin-5-ylmethyl or 2,4-dioxooxazolidin-5-ylmethyl group is present in the molecule, the carbon atom at the 5-position is asymmetric. Although these isomers are all represented herein by a single molecular formula (XIV), the present invention includes both the individual, isolated isomers and mixtures, including racemates, thereof and the isomers may be present in such mixtures in any proportions. Where stereospecific synthesis techniques are employed or optically active compounds are employed as starting materials, individual isomers may be prepared directly; on the other hand, if a mixture of isomers is prepared, the individual isomers may be obtained by conventional resolution techniques. The compounds of formula (XIV) which contain a 2,4-dioxothiazolidin-5-ylmethyl or 2,4-dioxooxazolidin-5-ylmethyl group can exist in the form of various tautomeric isomers as shown in the following schemes α and γ, respectively: In the above formula (XIV), all tautomers based thereon and mixtures of equivalent weights or non-equivalent weights of these tautomers are represented by one formula. Thus, all of these isomers and mixtures of these isomers are included in the present invention. Moreover, the present invention also includes all solvates, for example hydrates, of the compounds of formula (XIV) and salts thereof, where the relevant compound is capable of forming a solvate. The invention also embraces all compounds which could be converted in the living mammalian, for example human, body to a compound of formula (XIV) or a salt thereof by the action of the metabolism, that is so-called "prodrugs" of the compounds of formula (XIV) and salts thereof. The compounds of the present invention may be prepared by a variety of processes well known in the art for the preparation of compounds of this general type. For example they may be prepared by the following Reaction Schemes D and E: Reaction Scheme D This process may be used to prepare compounds of formula (XIV) of the present invention. The compounds of formula (XIV) may then be used to prepare compounds of formula (I), described in more detail in EP-A-676398, in which Z represents a group of formula (ii) or (iii), that is a 2,4-dioxothiazolidin-5-ylmethyl or 2,4-dioxooxazolidin-5-ylmethyl group, i.e. compounds of formula (XV). In the above formulae: X is as defined above with respect to the compounds of formula (I), described in more detail in EP-A-676398, but preferably represents an imidazopyridyl or imidazopyrimidinyl group; Y, R and m are as defined above; Y' represents an oxygen or sulphur atom; Q represents a lower alkoxycarbonyl group, a formyl group, a protected formyl group, a carboxyl group or a hydroxy group; and Halo represents a halogen atom. Step D1 In Step D1, a compound of formula (XIV) is prepared by reacting a compound of formula (XII) with a compound of formula (XIII) in the presence of a base. There is no particular restriction on the nature of the base used, and any base commonly used in this type of reaction may equally be employed here. Examples of such bases include: inorganic bases, for example hydrides (such as sodium hydride or potassium hydride) and carbonates (such as potassium carbonate or sodium carbonate); and organic bases, such as triethylamine. The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents include: hydrocarbons, which may be aliphatic or aromatic, such as benzene, toluene, xylene, hexane or heptane; ethers, such as diethyl ether, tetrahydrofuran or dioxane; amides, such as dimethylformamide, dimethylacetamide or hexamethylphosphoric triamide; and mixtures of any two or more of these solvents. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at a temperature of from ice-cooling to heating, e.g. to the reflux temperature of the reaction mixture. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 0.5 hour to several days will usually suffice. The reaction is most preferably carried out with cooling or heating or at room temperature in an amides or a mixture of at least one amide with at least one other organic solvent, in the presence of sodium hydride for a period of from 1 to 10 hours. The compounds of formula (XIV), which are prepared by this method, are new compounds and are important intermediates for the preparation of the compounds of formula (I) described and exemplified in EP-A-676398 from which the present application is divided. These compounds of formula (XIV) thus comprise the present invention. Step D2 In Step D2, a compound of formula (XV) is prepared by one of the following two methods (a) and (b). Step D2(a) The compound of formula (XV) can be produced by reacting a compound of formula (XIV), in which Q represents a lower alkoxycarbonyl group, with a 2,3-diaminopyridine derivative or a 4,5-diaminopyrimidine derivative. The reaction is normally and preferably effected in the presence or the absence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents include: hydrocarbons, preferably aromatic hydrocarbons, such as benzene, toluene or xylene; ethers, such as diethyl ether, tetrahydrofuran or dioxane; amides, such as dimethylformamide, dimethylacetamide or hexamethylphosphoric triamide; alcohols, such as methanol, ethanol or butanol; acids, such as acetic acid or propionic acid; and mixtures of any two or more of these solvents. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction with heating, e.g. to the reflux temperature of the reaction mixture. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 3 hours to several days will usually suffice. The reaction is most preferably carried out in the absence of a solvent with heating at a temperature of from 50°C to 150°C for a period of from 5 hours to 2 days. Step D2 (b) As an alternative, the compound of formula (XV) can be produced by reacting a compound of formula (XIV), in which Q represents a formyl group, in a first stage, with a 2,3-diaminopyridine derivative or a 4,5-diaminopyrimidine derivative, and then, in a second stage, treating the product with an oxidising agent. The reaction is normally and preferably effected in the presence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents include: hydrocarbons, which may be aliphatic or aromatic, such as benzene, toluene, xylene, hexane or heptane; ethers, such as diethyl ether, tetrahydrofuran, dioxane or 1,2-dimethoxyethane; amides, such as dimethylformamide, dimethylacetamide or hexamethylphosphoric triamide; alcohols, such as methanol, ethanol or isopropanol; acids, such as acetic acid or propionic acid; sulphoxides, such as dimethyl sulphoxide; and mixtures of any two or more of these solvents. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction at about room temperature or with heating, e.g. to the reflux temperature of the reaction mixture. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 1 hour to several days will usually suffice. The product is then treated, in the second stage, with an oxidising agent. There is no particular restriction on the nature of the oxidising agent used, and any oxidising agent commonly used in this type of reaction may equally be employed here. Examples of such oxidising agents include iodine, silver oxide and lead tetraacetate, of which we prefer iodine. The treatment with the oxidising agent is normally and preferably effected in the presence of a solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved and that it can dissolve the reagents, at least to some extent. Examples of suitable solvents include the solvents cited above for use in the first stage, preferably the ethers. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. In general, we find it convenient to carry out the reaction with heating. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from 1 hour to several days will usually suffice. In the compound of formula (XIV), where Q represents a protected formyl group, the formyl-protecting group may be removed prior to subjecting the compound to the reaction of Step D2. Examples of such protected formyl groups include: for example, the dimethoxymethyl, diethoxymethyl, 1,3-dioxan-2-yl, 1,3-dioxolan-2-yl, 1,3-dithian-2-yl and 1,3-dithiolan-2-yl groups. The formyl-protecting group can be removed by conventional methods well known in the art, for example by contacting the compound of formula (XIV) with a conventional deprotecting agent under the conditions conventionally used for deprotection. These conditions are described in T. W. Green: Protective Groups in Organic Synthesis (John Wiley & Sons Ed.) or J. F. W. McOmie: Protective Groups in Organic Chemistry (Plenum Press Ed.). Reaction Scheme E This process may also be used to prepare compounds of formula (XIV) of the present invention. The compounds of formula (XIV) may then be used to prepare compounds of formula (I), described in more detail in EP-A-676398 in which Z represents a group of formula (ii) or (iii), that is a 2,4-dioxothiazolidin-5-ylmethyl or 2,4-dioxooxazolidin-5-ylmethyl group, i.e. compounds of formula (XV). In the above formulae, Q, Y, Y', R and m are as defined above; Step E1 In Step E1, a compound of formula (XVII) is prepared by reacting a compound of formula (XII) with a compound of formula (XVI) with a base. This reaction is essentially the same as that described in Step D1 of Reaction Scheme D, and may be carried out using the same reagents and reaction conditions. Step E2 In Step E2, a compound of formula (XVIII) is prepared by reducing a compound of formula (XVII). The reaction may be carried out by a conventional catalytic hydrogenation or by using any reducing agent capable of reducing a nitro group, such as zinc-acetic acid or tin-hydrochloric acid. Step E3 In Step E3, a compound of formula (XIX) is prepared by subjecting a compound of formula (XVIII) to a Meerwein arylation reaction. The conditions employed for the reaction are well known and are generally similar to those disclosed in Japanese Patent Kokai Application No. Sho 55-22657 or reported by S. Oae et al .: Bull. Chem. Soc. Japan, 53 , 1065 (1980). Step E4 In Step E4, a compound of formula (XIV) is prepared by reacting a compound of formula (XIX) with urea or thiourea and then subjecting the product to hydrolysis. The conditions employed for this reaction are well known and are generally similar to those disclosed in Japanese Patent Kokai Application No. Sho 55-22657. Step E5 In Step E5, a compound of formula (XV) is prepared from the compound (XIV), by one of Steps D(a) and D(b). The reaction is exactly the same as that shown in those Steps and may be carried out using the same reagents and reaction conditions. In the steps described above, the products of each step can, if desired, be recovered from the reaction mixture by conventional means at the end of each reaction and, if necessary, the compounds obtained can be further purified by conventional means, for example, by column chromatography, recrystallisation, reprecipitation or similar well known procedures. An example of one such technique comprises: adding a solvent to the reaction mixture; extracting the desired compound; and finally distilling off the solvent from the extract. The residue obtained may be purified by column chromatography through silica gel or like adsorbent to afford the desired compound as a pure specimen. The present invention is further illustrated by the following non-limiting Examples. Preparation of certain of the starting materials used in some of these Examples is illustrated by the subsequent Preparations. Preparation of the compounds of formula (I) from the compounds of formula (XIV) of the present invention is described in detail in EP-A-676398 to which appropriate references are made. EXAMPLE 1 5-[4- (Ethoxycarbonylmethoxy)benzyl]-thiazolidine-2,4-dione (This compound is identical to Preparation 39 of EP-A-676398) A solution of 100 g of methyl 4-(2-bromo-2-butoxycarbonylethyl)phenoxyacetate (prepared as described in Preparation 11) and 22 g of thiourea in 200 ml of ethanol was heated under reflux for 2.5 hours. After that, 2 N aqueous hydrochloric acid was added to the mixture, and the resulting mixture was heated under reflux for 5 hours. At the end of this time, the reaction mixture was freed from the solvent by distillation under reduced pressure. The resulting residue was diluted with water, after which it was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulphate, and the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography through silica gel, using a 2 : 5 by volume mixture of ethyl acetate and hexane as the eluent, to give 19.4 g of the title compound, melting at 105 - 106°C. The title compound may be used to prepare the compound of Example 15 of EP-A-676398, to which reference is made. EXAMPLE 2 5-[4-(2,2-Diethoxyethoxy)benzyl]thiazolidine-2,4-dione (This compound is identical to Preparation 46 of EP-A-676398) 530 mg of 5-(4-hydroxybenzyl)thiazolidine-2,4-dione were added to a suspension of 260 mg of sodium hydride (as a 55% by weight dispersion in mineral oil, and which had previously been washed with toluene) in 5 ml of dimethylformamide, whilst cooling with ice, and the resulting mixture was stirred at room temperature for 30 minutes. At the end of this time, 0.73 ml of bromoacetaldehyde diethyl acetal was added to the mixture, whilst cooling with ice, and the resulting mixture was stirred at 50°C for 3 hours. The reaction mixture was freed from dimethylformamide by distillation under reduced pressure. The resulting residue was diluted with water and the aqueous mixture was adjusted to a pH of from 2 to 3 by the addition of 1 N aqueous hydrochloric acid, after which it was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulphate, after which the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography through silica gel, using a 2 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 600 mg of the title compound having Rf = 0.46 (on silica gel thin layer chromatography using a 2 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent). EXAMPLE 3 5-[4-(2-Oxoethoxy)benzyl]thiazolidine-2,4-dione (This compound is identical to Preparation 47 of EP-A-676398) 20 ml of 6 N aqueous hydrochloric acid were added to a solution of 10.07 g of 5-[4-(2,2-diethoxyethoxy)-benzyl]thiazolidine-2,4-dione (prepared as described in Example 2) in 80 ml of tetrahydrofuran, and the resulting mixture was allowed to stand overnight at room temperature. At the end of this time, the reaction mixture was freed from the solvent by distillation under reduced pressure. The residue was diluted with water, after which it was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulphate and the solvent was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography through silica gel, using a 2 : 3 by volume mixture of hexane and ethyl acetate as the eluent, to give 5.92 g of the title compound having Rf = 0.37 (on silica gel thin layer chromatography using a 1 : 2 by volume mixture of hexane and ethyl acetate as the developing solvent). The title compound may be used to prepare the compounds of Examples 18, 20 and 27 of EP-A-676398 to which reference is made. EXAMPLE 4 5 -{4 - [2-(1,3-Dioxolan -2 -yl)ethoxy ]benzyl}-thiazolidine-2,4-dione (This compound is identical to Preparation 106 of EP-A-676398) A procedure similar to that described in Example 2 was repeated, except that 15.0 g of 5-(4-hydroxybenzyl)thiazolidine-2,4-dione, 8.80 g of sodium hydride (as a 55% by weight dispersion in mineral oil), 17 ml of 2-(2-bromoethyl)-1,3-dioxolane and 80 ml of dimethylformamide were used, and that the product was purified by column chromatography through silica gel, using a 1 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 6.67 g of the title compound, melting at 102 - 104°C. EXAMPLE 5 5-[4- (3 -Oxopropoxy )benzyl]thiazolidine -2,4 -dione (This compound is identical to Preparation 107 of EP-A-676398) A solution of 6.30 g of 5-{4-[2-(1,3-dioxolan-2-yl)ethoxy]benzyl}thiazolidine-2,4-dione (prepared as described in Example 4) in 50 ml of a 4 : 1 mixture of acetic acid and water was stirred at 60°C for 6 hours. At the end of this time, the reaction mixture was freed from the solvent by distillation under reduced pressure. The resulting residue was purified by column chromatography through silica gel, using a 1 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 2.20 g of the title compound, melting at 48 - 51°C. The title compound may be used to prepare the compound of Example 34 of EP-A-676398 to which reference is made. PREPARATION 1 (reference) 5-{4-[2- (Indol-1-yl )ethoxy ]benzyl}thiazolidine-2,4-dione (Compound No. 1-1 of EP-A-676398) A solution of 2.05 g of 5-{4-[2-(indol-1-yl)-ethoxy]benzyl]-3-triphenylmethylthiazolidine-2,4-dione (prepared as described in Preparation 8) in 100 ml of dioxane was stirred in an atmosphere of hydrogen and in the presence of 3.1 g of 10% w/w palladium-on-charcoal, first at room temperature for 30 minutes, then at 60°C for 2 hours and then at 80°C for 3 hours. At the end of this time, the reaction mixture was filtered to remove the catalyst and the filtrate was concentrated by evaporation under reduced pressure. The concentrate was then purified by column chromatography through silica gel, using a 2 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 1.06 g of the title compound, melting at 42.3 - 44.6°C. PREPARATION 2 (reference) Ethyl indoline-2-carboxylate A mixture of 25.2 g of indoline-2-carboxylic acid, 50 ml of ethanol and 200 ml of a 4 N solution of hydrogen chloride in dioxane was stirred at room temperature for 3 days. At the end of this time, the reaction mixture was poured into an aqueous solution of potassium carbonate, after which it was extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium. chloride and dried over anhydrous sodium sulphate. The solvent was removed by distillation under reduced pressure, and the residue thus obtained was purified by column chromatography through silica gel, using a 2 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 28.1 g of the title compound having Rf = 0.81 (on silica gel thin layer chromatography using a 2 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent). PREPARATION 3 (reference) Indolin-2-ylmethanol A solution of 5.12 g of ethyl indoline-2-carboxylate (prepared as described in Preparation 2) in 20 ml of anhydrous tetrahydrofuran was added dropwise, whilst ice-cooling, to a mixture of 1.20 g of lithium aluminium hydride and 80 ml of anhydrous tetrahydrofuran, and the resulting mixture was stirred at room temperature for 2 hours. After this, an excess of sodium sulphate decahydrate was added to the mixture, which was then stirred for 20 minutes. At the end of this time, insoluble materials were filtered off and the filtrate was concentrated by evaporation under reduced pressure. The concentrate was purified by column chromatography through silica gel, using a 3 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 3.81 g of the title compound having Rf = 0.16 (on silica gel thin layer chromatography using a 2 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent). PREPARATION 4 (reference) 1-t-Butoxycarbonyl-2-hydroxymethylindoline 6.2 ml of di-t-butyl dicarbonate were added dropwise to a solution of 4.0 g of indolin-2-ylmethanol (prepared as described in Preparation 3) and 3.8 ml of triethylamine in 40 ml of anhydrous tetrahydrofuran, and the resulting mixture was stirred at room temperature for 10 hours. At the end of this time, the reaction mixture was poured into water, after which it was extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium chloride and dried over anhydrous sodium sulphate. The solvent was then removed by distillation under reduced pressure, and the resulting residue was purified by column chromatography through silica gel, using a 5 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 5.57 g of the title compound having Rf = 0.46 (on silica gel thin layer chromatography using a 2 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent). PREPARATION 5 5-[4-(1-t-Butoxycarbonylindolin-2-ylmethoxy)benzyl]-3-triphenylmethylthiazolidine-2,4-dione A solution of 6.6 g of 1,1'-(azodicarbonyl)di-piperidine in 10 ml of anhydrous tetrahydrofuran and 20 ml of anhydrous dimethylformamide was added dropwise to a mixture of 6.5 g of 1-t-butoxycarbonyl-2-hydroxymethylindoline (prepared as described in Preparation 4), 6.5 ml of tributylphosphine, 12.2 g of 5-(4-hydroxybenzyl)-3-triphenylmethylthiazolidine-2,4-dione [prepared as described in European Patent Publication No. 549 365A1] and 100 ml of anhydrous tetrahydrofuran, and the resulting mixture was stirred at room temperature for about 20 hours. At the end of this time, insoluble materials were filtered off and the filtrate was concentrated by evaporation under reduced pressure. The concentrate thus obtained was purified by column chromatography through silica gel, using a 10 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 3.70 g of the title compound, melting at 85.4 - 87.2°C. PREPARATION 6 (reference) Methyl indol-1-ylacetate A solution of 5.0 g of indole in 20 ml of dimethylformamide was added dropwise, whilst ice-cooling, to a mixture of 2.0 g of sodium hydride (as a 55% by weight dispersion in mineral oil, and which had previously been washed with hexane) and 80 ml of dimethylformamide, and the resulting mixture was stirred at room temperature for 1 hour. At the end of this time, 4.5 ml of methyl bromoacetate were added dropwise, whilst ice-cooling, to the mixture, which was then stirred at room temperature for 2 hours. After it had been stirred for this time, the reaction mixture was poured into ice-water, and then it was extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium chloride and dried over anhydrous sodium sulphate. The solvent was then removed by distillation under reduced pressure, and the resulting residue was purified by column chromatography through silica gel, using a 10 : 1 by volume mixture of hexane and ethyl acetate as the eluent, to give 6.52 g of the title compound having Rf = 0.66 (on silica gel thin layer chromatography using a 2 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent). PREPARATION 7 (reference) 2-(Indol-1-yl)ethanol A procedure similar to that described in Preparation 2 was repeated, except that 6.20 g of methyl indol-1-yl-acetate (prepared as described in Preparation 6), 1.50 g of lithium aluminium hydride and 220 ml of anhydrous tetrahydrofuran were used, to give 5.25 g of the title compound having Rf = 0.33 (on silica gel thin layer chromatography using a 2 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent). PREPARATION 8 (reference) 5-{4-[2-(Indol-1-yl)ethoxy]benzyl}-3-triphenylmethylthiazolidine-2,4-dione A procedure similar to that described in Preparation 5 was repeated, except that 2.0 g of 2-(indol-1-yl)-ethanol (prepared as described in Preparation 7), 4.81 g of 5-(4-hydroxybenzyl)-3-triphenylmethylthiazolidine-2,4-dione, 3.1 ml of tributylphosphine, 3.20 g of 1,1'-(azodicarbonyl)dipiperidine and 60 ml of anhydrous benzene were used, to give 5.69 g of the title compound, melting at 63.5 - 65.9°C. PREPARATION 9 Methyl 4-nitrophenoxyacetate A solution of 56 g of 4-nitrophenol, 90 g of methyl bromoacetate and 100 g of potassium carbonate in 500 ml of dimethylformamide was stirred at room temperature for 2 days. At the end of this time, the reaction mixture was freed from dimethylformamide by distillation under reduced pressure. The residue thus obtained was diluted with water, after which it was extracted with ethyl acetate. The extract was washed with water and dried over anhydrous sodium sulphate, after which the solvent was removed by distillation under reduced pressure. The resulting residue was crystallised by trituration with hexane, to give 63.3 g of the title compound, melting at 98 - 99°C. PREPARATION 10 Methyl 4-aminophenoxyacetate A procedure similar to that described in Preparation 1 was repeated, except that 30.8 g of methyl 4-nitrophenoxyacetate (prepared as described in Preparation 9), 5.0 g of 10% w/w palladium-on-charcoal and 500 ml of methanol were used, to give 25.8 g of the title compound having Rf = 0.79 (on silica gel thin layer chromatography using.ethyl acetate as the developing solvent). PREPARATION 11 Methyl 4-(2-bromo-2-butoxycarbonylethyl)phenoxyacetate 98 g of 47% w/v aqueous hydrobromic acid and subsequently 33 ml of an aqueous solution containing 12.8 g of sodium nitrite were added dropwise to a solution of 25.8 g of methyl 4-aminophenoxyacetate (prepared as described in Preparation 10) in 263 ml of a 2 : 5 by volume mixture of methanol and acetone, whilst cooling with ice, and the resulting mixture was stirred for 30 minutes whilst cooling with ice. 18.2 g of butyl acrylate were then added. The mixture was then stirred for 30 minutes while cooling with ice, after which 3.2 g of copper(I) bromide were added and the resulting mixture was stirred overnight at room temperature. At the end of this time, the reaction mixture was freed from the solvent by distillation under reduced pressure. The residue was diluted with an aqueous solution of sodium chloride and extracted with ethyl acetate. The extract was washed with an aqueous solution of sodium chloride and dried over anhydrous sodium sulphate, after which the solvent was removed by distillation under reduced pressure, to give 51.7 g of a crude product containing the title compound and having Rf = 0.46 (on silica gel thin layer chromatography using a 5 : 1 by volume mixture of hexane and ethyl acetate as the developing solvent).

Claims: A compound of formula (XIV) : wherein: each of Y and Y' independently represents an oxygen atom or a sulfur atom; R represents a hydrogen atom, an alkyl group having from 1 to 4 carbon atoms, an alkoxy group having from 1 to 4 carbon atoms, a halogen atom, a hydroxy group, a nitro group, an aralkyl group in which an alkyl group having from 1 to 5 carbon atoms is substituted by an aryl group having from 6 to 10 ring carbon atoms, or a group of formula -NR a R b , wherein R a and R b are the same or different and each represents a hydrogen atom, an alkyl group having from 1 to 8 carbon atoms, an aralkyl group in which an alkyl group having from 1 to 5 carbon atoms is substituted by an aryl group having from 6 to 10 ring carbon atoms, an aryl group having from 6 to 10 ring carbon atoms, an aliphatic carboxylic acyl group having from 1 to 11 carbon atoms, an aliphatic carboxylic acyl group which has from 2 to 6 carbon atoms and which is substituted by an aryl group having from 6 to 10 ring carbon atoms, or an aromatic carboxylic acyl group in which the aryl part has from 6 to 10 ring carbon atoms, m is an integer of from 1 to 5; Q represents a lower alkoxycarbonyl group, a formyl group, a protected formyl group or a carboxyl group; and salts thereof.

Inventors: HIROAKI YANAGISAWA, HIROYOSHI HORIKOSHI, KOICHI FUJIMOTO, KUNIO WADA, MINORU OGUCHI, TAKAO YOSHIOKA, TAKASHI FUJITA, TOSHIHIKO FUJIWARA, HIROAKI, YANAGISAWA, HIROYOSHI, HORIKOSHI, KOICHI, FUJIMOTO, KUNIO, WADA, MINORU, OGUCHI, TAKAO, YOSHIOKA, TAKASHI, FUJITA, TOSHIHIKO, FUJIWARA, TAKASHI, FUJITA, C/O SANKYO CO., LTD.
Applicants: SANKYO CO, SANKYO COMPANY LIMITED
Application year: 1995
Main classification: C07D263
IPC codes: C07D471, C07D209, C07D277, C07D413, C07D417, C07D487